Mercer, a business of Marsh McLennan (NYSE: MMC) and a global leader in helping clients realize their investment objectives, ...

For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published online July 9 in ...

Men were three times more likely than women to say GLP-1s boosted their confidence and two times more likely to say they were going on more dates. They also reported higher libido, more matches and ...

People who use GLP-1 weight loss drugs like Ozempic are more likely to suffer from severe acid reflux, or GERD, a new ...

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

Telehealth firm NextMed accused of hiding costs and faking positive reviews FTC alleges misleading weight-loss promises and ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX) is one of the best low priced pharma stocks to buy now. On July 13, Amylyx Pharmaceuticals announced new exploratory analyses from its Phase 2 PREVENT and ...

Adrenal adenomas were associated with attenuated weight loss among patients with obesity or overweight using GLP-1 or GIP/GLP ...

A glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist developed by Jiangsu Hengrui Pharmaceuticals Co. Ltd. and licensed by Kailera Therapeutics Inc. has ...

In this population-based cohort study, patients with type 2 diabetes who received glucagon-like peptide-1 receptor agonists had a higher risk of developing gastroesophageal reflux disease and ...

If you’re struggling with your body image this summer, there is still time to reach your image goals. Robert Andrews Laser & Medical Aesthetics is here to help you out this summer.